Minimal Residual Disease Testing Market Trends

Minimal Residual Disease Testing Market Trends

The increasing prevalence of cancer is anticipated to proliferate market growth in the coming years. The growing geriatric population suffering from cancer has accelerated the progress for diagnostic procedures that has further propelled the market expansion positively. Cancer including blood cancer, lymphoma, and solid tumors among others promote substantial disease burden. These ailments inflict health care costs and affect the health-associated quality of life.
 

According to the Leukemia and Lymphoma Society, in 2022, around 1.24 million blood cancer cases occurred across the globe that include a variety of chronic medical conditions. In addition, solid tumors represent around 90% of adult human cancers that leads to a large number of patients opting for minimal residual disease testing for diagnosis.
 

Furthermore, several government organizations across the globe have implemented strict regulations and recommendations to continuously monitor the treatment efficacy of patients suffering from cancer. Likewise, hospitals and clinics have focused more on continuous testing during treatment procedures. The surge in the prevalence & morbidity associated with cancer is amongst the key variables that are set to prove beneficial for the market.
 

Minimal residual disease testing market players and governments are collaboratively emphasizing on providing highly sensitive & specific diagnosis during treatment procedures that have resulted in aligning the minimal residual disease testing as an essential tool in healthcare facilities. As a result, the rise in in-patient hospitalization for various diagnosis and treatments is projected to fuel the minimal residual disease testing adoption.